“Lessons from the pandemic, now is an opportunity” … Small and medium-sized enterprises (SMEs) to create new growth engines

[헬스코리아뉴스 / 임도이] As the importance of the health care industry has increased significantly with the outbreak of COVID-19, the movement of companies to develop new treatments or medical technologies is becoming more active. It shows the will to create a new growth engine by using the unprecedented pandemic (infectious disease pandemic) as an opportunity. Although there is a burden of investment, SMEs with weak financial power are more active and attract attention.

Abclone, Challenge for Joint Development of CAR-T Treatment for Intractable Solid Cancer with National Cancer Center

According to related industries on the 8th, Abclone (CEO Lee Jong-seo), a company specializing in antibody drug development, recently conducted joint research with the National Cancer Center to develop a CAR (autologous chimeric antigen receptor)-T cell therapy targeting Claudin (CLDN)-18.2. signed a contract

Through this joint research, the two organizations agreed to fully mobilize their independent platform technology to develop a CAR-T cell therapy for the treatment of intractable solid cancer.

The National Cancer Center research team develops a platform technology that activates the killing ability of T cells only against cancer cells and a source technology for gene therapy using CAR-T cells that target antigens present only in cancer cells. We plan to develop a CAR-T cell therapy targeting the antigen Claudin-18.2. Through this, the strategy is to apply it to metastatic solid cancer that is refractory to existing treatment and recurs.

In particular, in the development of antibodies among the components of CAR (Chimeric Antigen Receptor) that will act on the Claudin-18.2 antigen, Professor Junho Jung, Department of Biochemistry, Seoul National University College of Medicine, an authority on antibody drugs and CAR-T cell therapy research, is participating, raising expectations for the research results. there is.

Abclone researchers, a company specializing in antibody drug development, are concentrating on R&D for new drugs to overcome incurable diseases such as solid cancer and blood cancer. [2022-04-08]
Abclone researchers, a company specializing in antibody drug development, are concentrating on R&D for new drugs to overcome incurable diseases such as solid cancer and blood cancer. [2022-04-08]

Professor Jung Jun-ho explained, “Cludin-18.2 is overexpressed in gastric and pancreatic cancers, so it is judged as a potent target to solve the unmet needs of patients with intractable solid cancer.”

An Abclone official said in a phone call with Health Korea News on the same day, “Recently, with the epochal success of CAR-T cell therapy for blood cancer, research to expand and apply it to intractable solid cancer is being actively conducted around the world, but solid cancer is Due to various difficulties such as the tumor environment, positive clinical results as effective as the treatment for blood cancer have not yet been reported,” he explained.

Abclone is currently conducting phase 1 clinical trials in Korea for ‘AT101’, a blood cancer CAR-T cell therapy. A company official said, “In addition to the blood cancer treatment currently in clinical trials, we want to provide patients with various treatment opportunities by succeeding in developing a solid cancer CAR-T cell treatment. It will be an opportunity to leap forward as a leading T cell therapy company.”

NK Max, the first patient in Phase 1/2a clinical trial of a targeted NK cell therapy

NK Max, an NK cell therapy development company, entered a global clinical trial for a targeted NK cell therapy jointly developed by its US subsidiary NKGen Biotech. finished

This phase 1/2a clinical trial is conducted in the form of co-administration of NK Max’s NK cell treatment drug ‘SNK01’ and Apimed’s EGFR-targeting dual antibody drug ‘AFM24’. ‘SNK01-AFM24’ is a mechanism that connects EGFR-expressing cancer cells and NK cells to induce cancer cell death through ADCC (Antibody Dependent Cellular Cytotoxicity) of NK cells.

This clinical trial is aimed at 139 patients with three types of EGFR-positive solid cancer (metastasis colorectal cancer, head and neck squamous cell carcinoma, and non-small cell lung cancer), and will be conducted simultaneously at up to 15 institutions in the United States. Phase 1 safety evaluation and phase 2 dosage will be determined, and phase 2a efficacy will be evaluated by cancer type.

Park Sang-woo, CEO of NK Max, told Health Korea News on the 8th, “We are expecting an excellent combination of Super NK with high activity and AFM24 with cancer cell targeting ability. It can be supplemented, so it will become a technology that can replace CAR-NK in the future.”

Chaperone, Alzheimer’s dementia treatment new drug preclinical results presented by the American Society of Immunology

A view of the Chaperon Hongcheon Research Center.
A view of the Institute of Systems Immunology Medicine, Seoul National University, Hongcheon, Gangwon-do, which is conducting research on chaperone clinical projects.

Chaperon (co-CEO Seung-yong Seong and Myung-se Lee), a new drug development bio company, will officially announce the preclinical results of ‘NuCerin’, an Alzheimer’s dementia treatment, at the Immunology 2022 meeting in May.

The American Association of Immunologists (AAI)’s ‘Immunology 2022’ is a global academic conference where immunology officials from around the world share the latest research results and form a network. This event will be held in Portland, Oregon, USA from May 6th to 10th (local time).

At this event, Chaperon plans to present the preclinical results of ‘NuCerin’, an Alzheimer’s dementia treatment based on Chaperone’s GPCR19-P2X7-regulated NLRP3 Inflammasome inhibitor, in oral and poster format.

Chaperone’s ‘NuCerin’ is a new drug candidate for patients with mild to moderate Alzheimer’s dementia. In particular, ‘NuCerin’ strongly inhibits the production of IL-1β and TNF-α in microglia, which are being studied as the main cause of Alzheimer’s dementia, at the same time, thereby alleviating neuroinflammation from the early stage of the disease as well as phagocytes. The company explained that it reduces dementia-inducing factors by increasing the action.

In preclinical animal model experiments, chaperone confirmed not only a significant decrease in amyloid beta plaque, which is targeted by many therapeutic agents, but also normalization of neurons and improvement of cognitive ability, the ultimate goal of treatment. This research result of Chaperone was recently published in ‘Frontiers in Immunolody’, an internationally renowned SCI-level academic journal.

Chaperone signed a technology transfer (L/O) contract with Kukjeon Pharm for ‘NuCerin’ in March last year, and in November, it received approval for a domestic phase 1 clinical trial (IND) from the Ministry of Food and Drug Safety and is currently preparing to start. .

Seong-yong Seong and Myung-se Lee, co-CEOs of Chaperon, told Health Korea News on the 8th, “As the aging population accelerates, it is predicted that more than 153 million people around the world will suffer from dementia in 2050, but until now, the disease is reversible. He said, “Through this announcement, we will inform the global market about the strength of chaperone’s inflammatory complex inhibitor and proceed with clinical trials sequentially so that it can become a new alternative for Alzheimer’s dementia treatment.” .

Chaperone has its own technology to inhibit the inflammatory complex that simultaneously inhibits both the initiation and amplification stages of the inflammasome. NuGel) was developed. In addition, by reducing the weight of existing antibody therapeutics to 1/10, they are applying a nanobody-based next-generation antibody therapy that is easy to access genetically for the development of various formulations for the development of immuno-cancer drugs.

Ilias Biologics, Korea’s first emsosome-based treatment development clinical trial

Ilias Biologics (CEO Cheol-hee Choi, Tae-jin Ham) conducted a phase 1 clinical trial for ‘ILB-202’, a treatment for acute kidney injury (CSA-AKI) after cardiac surgery, from the Human Research Ethics Committee (HREC) of Australia on the 7th. Approved. This made it possible for Ilias to enter global clinical trials for exosome-based treatment for the first time in Korea.

ILB-202 is an exosome therapeutic agent loaded with srlκB (super-repressor lκB) protein, an anti-inflammatory substance that inhibits the action of NF-κB that activates inflammation. The srIκB protein suppresses the inflammatory response by preventing the NF-κB protein from entering the cell nucleus and acting. It was developed using Ilias’ platform technology EXPLOR®, which actively mounts high molecular weight pharmacological proteins inside exosomes using a protein module that binds by light.

Ilias plans to evaluate the safety and tolerability of ILB-202 in healthy adults in the first phase of the Australian clinical trial.

According to Ilias, in preclinical studies, its exosome treatment has proven its effectiveness in treating acute kidney injury. Ilias’ exosome treatment improved the renal function index and biomarker levels used in the diagnosis and prognosis of acute kidney injury in animal models before and after ischemia-reperfusion surgery. there is a bar

exosome
exosome

Acute kidney injury (AKI) is a disease in which kidney function is rapidly reduced due to various causes. In particular, it is known that 30% of patients undergoing cardiac surgery suffer from acute kidney injury, but there is still no effective treatment, so there are high unmet medical needs, and the development of a drug treatment to replace expensive dialysis therapy is urgently needed.

Cheol-hee Choi, co-CEO of Ilias, said, “With the full-scale clinical entry of ILB-202, which has proven its potential through preclinical studies, it is expected that we will take a step closer to developing an exosome treatment. In addition to controlling the inflammatory response more safely and effectively than existing treatments, it can be applied to various inflammatory diseases, so we plan to expand the scope of indications, starting with acute kidney injury.”

VUNO Announces AI-Based Liver Cancer Research Results at AACR 2022

VUNO (CEO Yeha Lee), a medical artificial intelligence solution company, will participate in the 2022 American Association for Cancer Research (AACR) annual conference held from the 8th to the 13th and present the results of AI-based liver cancer pathology research it has accumulated.

This research is an artificial intelligence-based digital pathology study for liver cancer, and it is the third study that VUNO is conducting and publishing with The University of Texas MD Anderson Cancer Center, one of the world’s best hospitals for cancer treatment. . The result of developing a data-based biomarker that predicts the prognosis of liver cancer using spatial analysis, which divides regions based on the distance from the border of cancer and analyzes them by region, and interprets the clinical meaning contains

The VUNO Pathology research team analyzed tissue slides from 351 liver cancer patients using its AI-based pathology research platform, VUNO Med®-PathLab™. The platform consists of a model that segments cancerous tissue into malignant cells, lymphocytes, mucus, and normal tissue and models that detect major cells. function that can be

As a result of the study, it was confirmed that the spatial distribution of macrophages (macrophages) and lymphocytes, which suppress the growth of cancer cells, among immune cells located at the border of cancer tissues, has a significant relationship with the prognosis of liver cancer. This suggests that checking the distribution and ratio of macrophages and lymphocytes through spatial analysis using an artificial intelligence model can be a significant biomarker predicting the prognosis of liver cancer.

Vuno CTO Gyu-hwan Gyu-hwan said, “This study is an important technical and clinical study in that it reveals important factors in predicting the prognosis of liver cancer through spatial analysis, which has recently become a trend in cancer research, and suggests the direction for AI-based digital pathology. “This event, which will be held offline for the first time in three years, will show VUNO’s excellent technology and research capabilities to more global researchers and specialists and will do our best to introduce precision medical solutions of high clinical value in the future. ” he said.

For reference, the American Association for Cancer Research (AACR), the world’s largest cancer society, is celebrating its 115th anniversary this year. Every year, pharmaceutical/bio experts and oncologists from 120 countries around the world participate to share and present cancer-related knowledge and the latest research results. This year’s AACR will be held offline in New Orleans, USA from April 8th to 13th local time for the first time in three years since the COVID-19 pandemic, and an online session will also be held during the same period.

DeepBio Acquires European CE-IVDD Certification for Prostate Cancer Diagnosis Aid AI

On the other hand, DeepBio (CEO Kim Seon-woo), a medical company specializing in AI-based cancer diagnosis, obtained the European Medical Device Certification (CE-IVDD) for its AI-based prostate cancer diagnosis assistant software ‘DeepDx Prostate’. It is the second CE-IVDD certification obtained in 2019, and the user experience has been improved for more convenient use.

DeepDx Prostate is a software that assists in cancer diagnosis by analyzing the Whole Slide Image (WSI) of the prostate needle biopsy tissue stained with Hematoxylin & Eosin with artificial intelligence to find the cancer area and classify the severity. Analysis results are provided as Gleason patterns 3, 4, 5, Gleason scores, and 5 Gleason grades according to the Gleason grading system, which is the most used method for classifying the degree of differentiation of prostate cancer tissues. It can help to increase the accuracy of diagnosis by automatically measuring the proportion of cancer in the entire tissue, the proportion of each Gleason pattern region, and the length of the tissue and cancer region.

With this CE certification, DeepBio will be able to supply the product to Europe as well. In addition, by adding momentum to European partnerships such as SECTRA of Sweden, a global PACS company, Tribun Healthcare, a leader in digital pathology in France, and HealthCare Konnect, a Swiss medical device distribution company, etc. It is expected to further strengthen Deep Bio’s position.

An official from Deep Bio said in a phone call with Health Korea News on the 8th, “This CE-IVDD certification was an opportunity to prove the expertise and confidence of Deep Bio technology.” Based on the meaningful research achievements shared at global academic conferences such as the AACR, we will actively expand overseas markets.”

DeepBio is currently conducting joint research with several leading universities and medical institutions at home and abroad, such as Stanford Medical School and the Dana-Farber Cancer Center, and is collaborating with pathological medical image management platform companies to provide services to more pathologists.

Alteogen recruits business development and licensing experts

Dr. Vivek Shenoy has been hired as Alteogen's Global Development Officer (CBO).
Dr. Vivek Shenoy has been hired as Alteogen’s Global Development Officer (CBO).

As such, some companies are focusing on developing new drugs or new medical technologies, while others are working hard to recruit talent.

Alteogen (CEO Park Soon-jae), a leading biobetter development company, undertook organizational restructuring to become a global bio company. As part of this, Dr. Vivek Shenoy was recruited as Chief Business Development Officer (CBO), which was vacant. He plans to contact potential customers in the United States and take charge of business development and licensing agreements.

Dr. Senoi has successfully worked in business development and licensing agreements for over 20 years at Astra Zeneca and Biocon, a global biosimilar company. In particular, Alteogen explained that it played a pivotal role in the process of licensing out the oral insulin IN-105 developed by Biocon to BMS.

Like Dr. Arun Swaminathan, a former CBO of Alteogen who successfully completed three deals, his wealth of experience and ability to actively participate in networks that play a pivotal role in the global pharmaceutical industry greatly influenced the recruitment. known to be crazy.

An Alteogen official told Health Korea News on the 8th, “Due to the resignation of the former CBO and restrictions on overseas access due to the corona virus, communication with companies or new companies in contact has been restricted. The discussion is gaining momentum and the number of new companies showing interest in the ALT-B4 hyaluronidase platform is increasing.

Alteogen also recruited Vice President Kim Hang-yeon, a former accountant, as the new CFO. This is to enhance financial transparency and safety by amending internal accounting regulations in line with IFRS. In addition, the IR organization is being reorganized to strengthen communication with investors.

Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited


Source: 헬스코리아뉴스 – 더뉴스 by www.hkn24.com.

*The article has been translated based on the content of 헬스코리아뉴스 – 더뉴스 by www.hkn24.com. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!

*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.

*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!